Patients with P/LP variants in CHEK2 (2.7%) developed PCa significantly earlier than non-carriers (8.9 years, p = 0.02), and some pathogenic variants were associated with an increased risk for aggressive disease [76]. The gene discussed is CHEK2; the disease is posterior cortical atrophy.